EUVIMEDEUVIMED entdecken
Crossref

Recurrence patterns following CRS-HIPEC in patients with colorectal peritoneal metastases: Insights from the Dutch CRS-HIPEC registry

T B M van den Heuvel, F N van Erning, P H J Hemmer, E V E Madsen, P R de Reuver, R J Wiezer, A J Witkamp, I H J T De Hingh

European Journal of Surgical Oncology · 2025

DOI: 10.1016/j.ejso.2025.110501 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Surgical Oncology, 2025. Verfasst von T B M van den Heuvel und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Catharina Cancer Institute, Eindhoven, the Netherlands; Department of Research and Development, Netherlands Comprehensive Canc…. Hauptthemen laut MEDLINE: Peritoneal Neoplasms, Colorectal Neoplasms, Hyperthermic Intraperitoneal Chemotherapy, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) is currently the only treatment with curative intent for selected patients with colorectal peritoneal metastases. This population-based study determined the 3-year cumulative incidence of disease recurrence after CRS-HIPEC, identified factors associated with disease recurrence and described how recurrent disease is treated. MATERIALS AND METHODS: All patients who underwent complete CRS-HIPEC for non-appendiceal colorectal peritoneal metastases with or without extra-peritoneal metastases in 2019 were selected from the Dutch CRS-HIPEC registry. Follow up data were collected in 2023-2024. Three-year cumulative incidence of recurrence was calculated. Multivariable Cox competing risk regression analysis was used to identify factors associated with recurrence. RESULTS: A total of 157 patients was analysed with a median follow-up of 31.0 (IQR 17.8-49.5) months. The 3-year cumulative incidence of disease recurrence was 86.3 %. Three-year recurrence-free and overall survival were 13.7 % and 47.8 % respectively. The most common sites of first recurrence were the peritoneum (68.2 %), liver (40.2 %) and lung (37.9 %). Treatment of recurrence was performed in 80.3 % of patients. Treatment mostly entailed systemic therapy (67.9 %). Secondary CRS-HIPEC was performed in 7.6 % of the patients. Factors associated with a higher risk of recurrence were a higher Peritoneal Cancer Index score (HR 1.06, 95 % CI 1.03-1.09) and pN2 (HR 2.07, 95 % CI 1.28-3.36). CONCLUSION: Most patients that underwent CRS-HIPEC for colorectal peritoneal metastases developed recurrent disease within 3 years. Future research should focus on ongoing developments in both diagnostics and treatment to prevent early recurrence.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Peritoneal NeoplasmsColorectal NeoplasmsHyperthermic Intraperitoneal ChemotherapyNeoplasm Recurrence, LocalCytoreduction Surgical ProceduresHumansFemaleMaleMiddle AgedRegistriesNetherlandsAgedIncidenceSurvival RateAdult

Stichwörter der Autor:innen

CRS-HIPECColorectal peritoneal metastasesPopulation-basedRecurrence

Autor:innen und Institutionen

  • Department of Surgery, Catharina Cancer Institute, Eindhoven, the Netherlands; Department of Research and Development, Netherlands Comprehensive Cancer Organization, Utrecht, the Netherlands; GROW - School for Oncology…
  • Department of Surgery, Catharina Cancer Institute, Eindhoven, the Netherlands; Department of Research and Development, Netherlands Comprehensive Cancer Organization, Utrecht, the Netherlands. Electronic address: f.vaner…
  • Department of Surgery, University Medical Center Groningen, Groningen, the Netherlands.
  • Department of Surgery, Erasmus University Medical Center, Rotterdam, the Netherlands.
  • Department of Surgery, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Department of Surgery, St. Antonius Hospital, Nieuwegein, the Netherlands.

Zitieren

APA

van den Heuvel, T. B. M., van Erning, F. N., Hemmer, P. H. J., Madsen, E. V. E., de Reuver, P. R., Wiezer, R. J., Witkamp, A. J., & De Hingh, I. H. J. T. (2025). Recurrence patterns following CRS-HIPEC in patients with colorectal peritoneal metastases: Insights from the Dutch CRS-HIPEC registry. European Journal of Surgical Oncology. https://doi.org/10.1016/j.ejso.2025.110501

Vancouver

van den Heuvel TBM, van Erning FN, Hemmer PHJ, Madsen EVE, de Reuver PR, Wiezer RJ, et al. Recurrence patterns following CRS-HIPEC in patients with colorectal peritoneal metastases: Insights from the Dutch CRS-HIPEC registry. European Journal of Surgical Oncology. 2025. doi:10.1016/j.ejso.2025.110501

BibTeX
@article{vandenHeuvel2025,
  author = {van den Heuvel, T B M and van Erning, F N and Hemmer, P H J and Madsen, E V E and de Reuver, P R and Wiezer, R J and Witkamp, A J and De Hingh, I H J T},
  title = {Recurrence patterns following CRS-HIPEC in patients with colorectal peritoneal metastases: Insights from the Dutch CRS-HIPEC registry},
  journal = {European Journal of Surgical Oncology},
  year = {2025},
  doi = {10.1016/j.ejso.2025.110501}
}
Kostenlos starten →